Correlates, surrogates, and vaccines

Journal of Infectious Diseases

Volumn 196, Issue 9, 2007, Pages 1279-1281

  Sadoff, Jerald C ^a   Wittes, Janet ^b  

^a Aeras Global TB Vaccine Foundation   (United States)

^b University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; ROTAVIRUS VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; BIOLOGICAL MARKER;

BACTERIAL INFECTION; CELLULAR IMMUNITY; CHICKENPOX; EDITORIAL; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA; INNATE IMMUNITY; MALARIA; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS; VARICELLA ZOSTER VIRUS; VERRUCA VULGARIS; VIRUS INFECTION; WART VIRUS; CLINICAL TRIAL; NOTE; POSTMARKETING SURVEILLANCE; VACCINATION;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; VACCINATION;

EID: 38449102544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522432     Document Type: Editorial

References (4)

1. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196:1304-12 (in this issue).
2. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
3. Rubin DB. Causal inference using potential outcomes: design, modeling, decisions. J Am Stat Assn 2005; 100:322-31.
4. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62:1161-70.